We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Antiepileptic treatment is associated with a small risk of suicidal thoughts and behaviour.
Do not prescribe ergots to patients who have had fibrosis in the heart, lungs, or abdomen.
Patients who take telbivudine and pegylated interferon are at increased risk of peripheral neuropathy and should stop taking both medicines if symptoms occur.
Patients with epilepsy should not take products that contain St John’s wort as any antiepileptic medicine may interact with St John’s wort.
To avoid the risk of air embolism, these products should not be infused under pressure.
Products that contain botulinum toxin are associated with the risk of serious adverse reactions due to distant spread of toxin.
Healthcare professionals should warn patients that compulsive behaviour with dopamine agonists may be dose-related.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).